Project description
Macrophages as a Trojan Horse against tumours
Macrophages are key players of the immune system and function by phagocytosing pathogens and foreign substances. They also have the ability to infiltrate tumours and promote or suppress tumour growth, making them a promising target for immunotherapy. The ERC-funded AGAINST project capitalises on the great promise of macrophage therapy and the ability of macrophages to uptake anti-cancer drugs and transfer them to solid tumours. This approach not only induces cancer cell death but also generates immunological memory upon tumour rechallenge. In this project, researchers will investigate the underlying mechanisms of this resistance as well as immune responses in mouse models. Project results have the potential to advance this technology for clinical application.
Objective
Macrophage therapy is promising for solid tumor treatment as these cells are continuously recruited into the tumor mass, even the most hypoxic regions. Our pioneering research demonstrated that macrophages are able to take up ferritins loaded with anti-cancer drugs, creating Macrophage-Drug Conjugates (MDCs), and transfer these to cancer cells and kill them, a phenomenon we named TRAIN. In my ongoing ERC Starting Grant PROJECT McHAP, we have proven that MDCs can be sucessfully used not only to treat solid tumors but also to induce subsequent resistance to the tumor re-challenge. Acquisition of resistance to tumor development after specific therapy is a 'Golden Grail' in oncology.
Now we aim to turn the MDC technology into a commercial and social value proposition by confirming mechanisms of tumor-resistance in tumor-bearing mice and identify immune response. This is crucial to raise interest of and establish a co-development (or licensing) deal with big pharmas to realize commercialization and clinical uptake of our IP-protected MDC technology. During the ERC PoC project, we will perform high-dimensional spectral flow cytometry, spatial transcriptomics and single-cell transcriptomics of the tumor before and after MDC treatment to identify mechanisms of tumor-resistance and optimize our business case. This project will thus provide proof of concept for the immune activation after the MDC treatment and thus establish the viability, feasibility, commercialization and overall direction for our innovative MDC technology. This project will substantially contribute to bring our MDC technology to the market and clinical practice.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.1.1 - European Research Council (ERC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) ERC-2022-POC2
See all projects funded under this callHost institution
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
02 787 WARSZAWA
Poland
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.